A phase I clinical study of autologous dendritic cell therapy in patients with relapsed or refractory multiple myeloma

Cellular immunotherapy is emerging as a potential immunotherapeutic modality in multiple myeloma (MM). We have developed potent immunotherapeutic agent (VAX-DC/MM) generated by dendritic cells (DCs) loaded with autologous myeloma cells irradiated with ultraviolet B. In this study, we evaluated the s...

Descripción completa

Detalles Bibliográficos
Autores principales: Jung, Sung-Hoon, Lee, Hyun-Ju, Lee, Youn-Kyung, Yang, Deok-Hwan, Kim, Hyeoung-Joon, Rhee, Joon Haeng, Emmrich, Frank, Lee, Je-Jung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522196/
https://www.ncbi.nlm.nih.gov/pubmed/28088784
http://dx.doi.org/10.18632/oncotarget.14582

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522196/
https://www.ncbi.nlm.nih.gov/pubmed/28088784
http://dx.doi.org/10.18632/oncotarget.14582

Ejemplares similares